



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@gene.go.com

Contact: Jean Holt
Director, Corporate Communications
Elsevier MDL
(925) 543-5400
j.holt@mdl.com

GENEGO AND ELSEVIER MDL COLLABORATE TO PROVIDE SEAMLESS ACCESS TO COMPOUND DATABASES, PATENTS, LITERATURE AND PATHWAYS

St. Joseph, Michigan, July 20th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis and Elsevier MDL, a leading provider of scientific content, informatics framework and workflow applications for pharmaceutical research, announced the collaboration. The latest version of GeneGo's data mining platform MetaCore 4.0 will be seamlessly integrated with the MDL[®] suite of databases via the DiscoveryGate[®] content platform. Researchers will be able to identify drug targets and bioactive compounds via pathway analysis and retrieve comprehensive information on their synthesis, biological effects, commercial availability and relevant literature within one application.

"The integration of MDL databases with GeneGo's pathways information systems enables scientists to bridge the gap between cell biology and organic chemistry," comments Steve Young, Director of MDL Content Strategy. "For the first time, biologists will be able to quickly review cheminformatics data of small molecules involved in biological pathways and chemists will be able to view molecular pathway information related to their lead compounds."

"Lately, a number of customers approached us with requests for functional analysis of the effects of drug-like compounds rather than genomic data," says Julie Bryant, VP Business development at GeneGo. "Although pathways and network analysis of bioactive compounds is a common practice in MetaCore, we partnered with Elsevier MDL for in depth coverage of literature and patent-derived information relevant for compounds. We are very pleased to be working with Elsevier MDL, the market leader in medicinal chemistry knowledge databases, Integration with the Elsevier MDL chemistry space opens up new applications for our products in medicinal chemistry, including high-throughput and high-content screening, hit selection and validation, lead development programs and chemogenomics."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery[™] platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.0[™], assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in

biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information visit www.elsevier.com.

MDL and DiscoveryGate are registered trademarks of MDL Information Systems, Inc. ('Elsevier MDL') in the United States and/or other countries. Beilstein Database: Copyright © 1988-2006, Beilstein-Institut zur Förderung der Chemischen Wissenschaften licensed to Beilstein GmbH and MDL Information Systems GmbH. All rights reserved.